Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer

NEXT STORY
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
PREV STORY
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

author_avatar
NASDAQ Market News

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Kymriah demonstrated an overall response rate of 50%, with median duration of response not ...

author_avatar
NASDAQ Market News

Human Papillomavirus Vaccine Market to Reach USD 12.69 Billion by 2027: Increasing Need to Reduce HPV Infections to Add Momentum, says Fortune Business Insights™

author_avatar
NASDAQ Market News